STA
PBYI icon

Summit Trail Advisors’s Puma Biotechnology PBYI Stock Holding History

Summit Trail Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,354
Closed -$154K – 195
2018
Q3 		$154K Buy
3,354
+1,587
+90% +$76.5K 0.03% 211
2018
Q2 		$105K Sell
1,767
-5,904
-77% -$342K 0.04% 208
2018
Q1 		$307K Buy
7,671
+2,041
+36% +$153K 0.05% 276
2017
Q4 		$383K Buy
+5,630
New +$630K 0.05% 271

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Summit Trail Advisors's PBYI Position: Q4 2018 in Review

Summit Trail Advisors sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 3,354 shares — an estimated $154K sold.

Summit Trail Advisors first reported a position in PBYI in Q4 2017 and held it in 4 quarters. The position peaked at $383K in Q4 2017. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Summit Trail Advisors reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 3,354 Puma Biotechnology shares in Q4 2018, an estimated $154K.
  • Summit Trail Advisors first reported a position in Puma Biotechnology in Q4 2017 and held it in 4 quarters.
  • Summit Trail Advisors's Puma Biotechnology position peaked at $383K in Q4 2017.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Summit Trail Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.